Live Q&A

Clinical Issues in Alzheimer’s Disease

Debates and Discussions About Diagnosis, New Therapies, and Healthcare Delivery

This activity is jointly provided by Global Education Group and Integritas Communications.

This activity is supported by an educational grant from Biogen MA, Inc.

Target Audience

This activity is designed to educate a multidisciplinary audience, including neurologists, geriatricians, and other clinicians involved in the management of patients with mild cognitive impairment (MCI) or early-stage Alzheimer’s disease (AD).

Program Description

This live question and answer session stems from materials discussed during the  Clinical Issuesin Alzheimer's Disease program at AAIC 2022 on July 31, 2022.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe clinically relevant aspects of Alzheimer’s disease pathophysiology, including amyloid β and tau
  • Evaluate patients with mild cognitive impairment or Alzheimer’s disease using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
  • Explain clinical trial data, challenges, and future directions with targeted therapies for early Alzheimer’s disease
  • Manage patients with early-stage Alzheimer’s disease through ongoing communication, shared decision making, and appropriate selection for treatment with targeted therapy


Marwan N. Sabbagh, MD, FAAN
Professor of Neurology, 
Alzheimer's Memory Disorders Division
Barrow Neurologicaal Institute
Research Professor, University of Arizona College of Medicine-Phoenix
Clinical Professor of Neurology
Creighton University
Phoenix, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

 This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour(s) (which includes 0.0 hour(s) of pharmacology). 

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN - Consulting: Alzheon, Inc., Biogen Inc,, Eisai Co., Ltd., F. Hoffmann-La Roche-Genentech, Inc., KeifeRx, Eli Lilly and Company, NeuroTherapia, Inc., Novo Nordisk A/S, Signant Health, Synaptogenix, Inc., T3D Therapeutics, Inc.; Stock Option Holder: Athira Pharma, Cognoptix Inc, Cortexyme, Inc., NeuroReserve, NeuroTau, Inc., Optimal Cognitive Health Company LLC, Seq Biomarque LLC, TransDermix, uMETHOD Health, Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP: Nothing to disclose
Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Gena Dolson, MS: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Global Contact Information

For information about the approval of this program, please contact Global at 303-395-1782.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this education activity. 

Register Now

You may receive up to 4 messages per live event.
Terms & Privacy Policy can be found below.
Message and data rates may apply. Reply STOP to end or HELP for help.

By clicking Register, you accept our Privacy Policy.